ID: ALA206515

Max Phase: Preclinical

Molecular Formula: C25H28N6O6S

Molecular Weight: 540.60

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)c2nc3ccccc3s2)CC1(C)C)C(=O)C(=O)Nc1cc[nH]n1

Standard InChI:  InChI=1S/C25H28N6O6S/c1-4-5-8-15(18(32)20(33)29-17-11-12-26-30-17)28-24(36)37-19-22(34)31(13-25(19,2)3)23(35)21-27-14-9-6-7-10-16(14)38-21/h6-7,9-12,15,19H,4-5,8,13H2,1-3H3,(H,28,36)(H2,26,29,30,33)/t15-,19+/m0/s1

Standard InChI Key:  YYMVVRDPBXFOTR-HNAYVOBHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 540.60

Molecular Weight (Monoisotopic): 540.1791

AlogP: 2.89

#Rotatable Bonds: 9

Polar Surface Area: 163.45

Molecular Species: NEUTRAL

HBA: 9

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 10.43

CX Basic pKa: 1.59

CX LogP: 4.22

CX LogD: 4.22

Aromatic Rings: 3

Heavy Atoms: 38

QED Weighted: 0.28

Np Likeness Score: -0.84

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature